Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
US-2021371404-A1 · Dec 2, 2021 · US
Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl- D3)pyridazine-3-carboxamide
US11649226B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11649226-B2 |
| Application number | US-202017131718-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 22, 2020 |
| Priority date | Mar 30, 2017 |
| Publication date | May 16, 2023 |
| Grant date | May 16, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula:Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
First claim
Opening claim text (preview).
What is claimed is: 1. A process for preparing Compound 7 of the formula comprising b) reacting compound 4a of the formula where X 3 is Cl, Br, I or F; with N-methyl-N-formylhydrazine and a suitable base to afford Compound 5a of the formula b) which is then nitrated to afford Compound 6a of the formula c) which is subsequently reduced to afford Compound 7. 2. A process for preparing Compound 7 of the formula comprising a) reacting compound 4 of the formula with N-methyl-N-formylhydrazine in the presence of potassium tert-butoxide to afford Compound 5 of the formula b) which is then reacted with nitric acid in the presence of concentrated sulfuric acid to afford Compound 6 of the formula c) which is subsequently reacted with hydrogen gas in the presence of Pd/C, sodium bicarbonate or sodium carbonate and methanol to afford Compound 7.
Assignees
Inventors
Classifications
Isotopically modified compounds, e.g. labelled · CPC title
to carbon atoms of non-condensed six-membered aromatic rings · CPC title
by reaction of hydroxy compounds with sulfonic acids or derivatives thereof · CPC title
having nitrogen atoms of carboxamide groups further acylated · CPC title
from amides by reaction at nitrogen atoms of carboxamide groups · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11649226B2 cover?
- The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula:Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
- Who is the assignee on this patent?
- Bristol Myers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification C07C209/62. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).